These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

954 related articles for article (PubMed ID: 32376855)

  • 41. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
    Madduri D; Hagiwara M; Parikh K; Pelletier C; Delea TE; Kee A; Chari A
    Future Oncol; 2021 Feb; 17(5):503-515. PubMed ID: 33522834
    [No Abstract]   [Full Text] [Related]  

  • 42. Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
    Hoy SM
    Drugs; 2017 Nov; 77(17):1897-1908. PubMed ID: 29110190
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
    Richardson PG; Perrot A; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Malinge L; Dubin F; van de Velde H; Anderson KC
    Lancet Oncol; 2022 Mar; 23(3):416-427. PubMed ID: 35151415
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Komarnicki M; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Lisby S; Khokhar NZ; O'Rourke L; Chiu C; Qin X; Guckert M; Ahmadi T; Moreau P;
    N Engl J Med; 2016 Oct; 375(14):1319-1331. PubMed ID: 27705267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L; Mistrík M; Bátorová A
    Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
    Alhaj Moustafa M; Parrondo R; Abdulazeez MF; Roy V; Sher T; Alegria VR; Warsame RM; Fonseca R; Rasheed A; Gonsalves WI; Kourelis T; Kapoor P; Buadi FK; Dingli D; Hayman SR; Reeder CB; Chanan-Khan AA; Ailawadhi S
    Anticancer Drugs; 2024 Jan; 35(1):63-69. PubMed ID: 37067996
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
    Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
    Lee HS; Kim K; Kim SJ; Lee JJ; Kim I; Kim JS; Eom HS; Yoon DH; Suh C; Shin HJ; Mun YC; Kim MK; Lim SN; Choi CW; Kang HJ; Yoon SS; Min CK;
    Am J Hematol; 2020 Apr; 95(4):413-421. PubMed ID: 31919872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
    Dimopoulos MA; Palumbo A; Corradini P; Cavo M; Delforge M; Di Raimondo F; Weisel KC; Oriol A; Hansson M; Vacca A; Blanchard MJ; Goldschmidt H; Doyen C; Kaiser M; Petrini M; Anttila P; Cafro AM; Raymakers R; San-Miguel J; de Arriba F; Knop S; Röllig C; Ocio EM; Morgan G; Miller N; Simcock M; Peluso T; Herring J; Sternas L; Zaki MH; Moreau P
    Blood; 2016 Jul; 128(4):497-503. PubMed ID: 27226434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
    Zagouri F; Roussou M; Kastritis E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Kalapanida D; Christoulas D; Migkou M; Terpos E; Dimopoulos MA
    Leuk Lymphoma; 2016 Aug; 57(8):1776-80. PubMed ID: 26916452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
    Sunami K; Matsue K; Suzuki K; Takezako N; Shinagawa A; Sakurai S; Tamakoshi H; Biyukov T; Peluso T; Richardson P
    Cancer Sci; 2020 Jun; 111(6):2116-2122. PubMed ID: 32297407
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
    Dima D; Mansour R; Davis JA; Minchak M; Goel U; Atallah R; Logan E; Tabak C; Rashid A; Ahmed N; Abdallah AO; Hashmi H
    Eur J Haematol; 2024 Jun; 112(6):975-983. PubMed ID: 38382632
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
    Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
    Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
    Richardson PG; Siegel DS; Vij R; Hofmeister CC; Baz R; Jagannath S; Chen C; Lonial S; Jakubowiak A; Bahlis N; Song K; Belch A; Raje N; Shustik C; Lentzsch S; Lacy M; Mikhael J; Matous J; Vesole D; Chen M; Zaki MH; Jacques C; Yu Z; Anderson KC
    Blood; 2014 Mar; 123(12):1826-32. PubMed ID: 24421329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
    Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
    Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
    Trudel S; Tessoulin B; Jullien M; Blin N; Gastinne T; Mahé B; Dubruille V; Bonnet A; Lok A; Chevallier P; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Le Gouill S; Moreau P; Touzeau C
    Ann Hematol; 2019 Jun; 98(6):1441-1447. PubMed ID: 30874851
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Daratumumab plus lenalidomide and dexamethasone
    Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
    Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
    Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
    J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.